IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Mr. Will Martin
従業員
44
国
スウェーデン
ISIN
SE0008321202
WKN
000A2H5NT
上場銘柄
0 Comments
意見をシェア
FAQ
Irras ABの株価は今日いくらですか?▼
IRRAS.ST の現在価格は SEK0.16 SEK で、過去24時間で -1.11% 下落しました。チャートで Irras AB 株価の動きを詳しく確認しましょう。